Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.
Although known for the important function in the immune system, MHC class I molecules are increasingly ascribed an alternative role in modifying signal transduction. In medulloblastoma, HLA class I molecules are associated with poor prognosis, and can induce ERK1/2 activation upon engagement with ligands that bind to incompletely assembled complexes (so called open conformers). We here demonstrate that ERK1/2 activation in medulloblastoma can occur in the absence of endogenously synthesized β2m, formally excluding involvement of closed HLA class conformation. In addition, several experimental observations suggest that heterogeneity of HLA class I expression may be a reflection of the status of original cells before transformation, rather than a consequence of immune-based selection of HLA-loss mutants. These results contribute to our understanding of an immune system-independent role of HLA class I in the pathology of medulloblastoma, and cancer in general.
Smith
Courtney
C
Center for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010-2970, USA.
Santi
Mariarita
M
Rushing
Elisabeth J
EJ
Cornelison
Robert
R
MacDonald
Tobey J
TJ
Vukmanovic
Stanislav
S
D015153:Blotting, Western; D002469:Cell Separation; D002528:Cerebellar Neoplasms / Q000276:immunology* / Q000378:metabolism; D002531:Cerebellum / Q000254:growth & development* / Q000378:metabolism; D002675:Child, Preschool; D005333:Fetus; D005434:Flow Cytometry; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis / Q000276:immunology*; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008527:Medulloblastoma / Q000276:immunology* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000502:physiology*
D015395:Histocompatibility Antigens Class I
Cancer Res. 2007 Jun 1;67(11):5471-8
17545629
Int J Cancer. 2001 Jan 20;95(1):23-8
11241306
J Immunol. 1989 Jun 1;142(11):3763-72
2469725
Immunogenetics. 1986;24(3):206-8
2428745
Bone Marrow Transplant. 2000 May;25 Suppl 2:S88-95
10933198
Cancer Immunol Immunother. 2006 Aug;55(8):891-9
16187081
Annu Rev Immunol. 1998;16:323-58
9597133
J Neuroimmunol. 2002 Oct;131(1-2):83-91
12458039
J Cell Biol. 1984 Feb;98(2):725-31
6319431
Int J Dev Neurosci. 2001 Feb;19(1):53-62
11226755
J Immunol. 2003 Aug 15;171(4):1918-26
12902494
Science. 1995 Jul 28;269(5223):549-52
7624779
Surg Neurol. 1988 Jun;29(6):435-42
3259730
Neuroreport. 1996 Nov 25;7(18):2951-5
9116217
J Transl Med. 2009 Jul 12;7:59
19594892
J Neuroimmunol. 1999 Nov 1;101(1):76-86
10580816
J Immunol. 1992 May 15;148(10):3202-9
1374450
Nature. 1995 May 25;375(6529):325-8
7753197
Nat Rev Neurosci. 2004 Jul;5(7):521-31
15208694
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15203-8
11752463
J Exp Med. 1997 Jan 20;185(2):305-16
9016879
J Immunol. 1997 Apr 1;158(7):3189-96
9120273
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6784-9
19346486
J Exp Med. 1994 Sep 1;180(3):841-50
8064236
Nature. 1984 Aug 23-29;310(5979):688-91
6433204
J Hematother Stem Cell Res. 2000 Dec;9(6):795-812
11177592
Am J Pathol. 2001 Oct;159(4):1219-24
11583948
Int J Cancer. 2006 Jan 1;118(1):6-10
16003753
Hum Immunol. 1986 Apr;15(4):347-56
2422143
Clin Exp Immunol. 1991 Apr;84(1):170-4
2015708
Mol Biol Cell. 1997 Dec;8(12):2463-74
9398668
Int J Cancer. 2005 Nov 1;117(2):248-55
15900607
Cancer Immunol Immunother. 2007 Feb;56(2):227-36
16783578
Eur J Immunol. 1994 Sep;24(9):2115-23
7916294
Arch Immunol Ther Exp (Warsz). 2001;49(3):195-201
11478393
PLoS One. 2007 Dec 26;2(12):e1354
18159237
Neurol Med Chir (Tokyo). 1990 Sep;30(9):649-55
1708454
J Exp Med. 1986 Aug 1;164(2):458-73
3088207
Neuron. 1998 Sep;21(3):505-20
9768838
Science. 2000 Dec 15;290(5499):2155-9
11118151
Nature. 1995 May 25;375(6529):328-31
7753198
J Immunol. 1994 Apr 1;152(7):3353-60
8144921
Eur J Immunol. 1987 Sep;17(9):1257-63
2443365
Neurosci Lett. 1988 Sep 23;92(1):8-13
3185980
Cancer Res. 2000 Dec 1;60(23):6617-22
11118044
Eur J Neurosci. 1999 Dec;11(12):4468-72
10594675
Curr Opin Neurol. 1999 Dec;12(6):681-5
10676748
J Neuroimmunol. 1989 Feb;21(2-3):117-23
2913044
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2153-6
11527924
J Neuropathol Exp Neurol. 1970 Oct;29(4):583-600
5471923
Science. 1996 Nov 15;274(5290):1133-8
8895456
Cell Immunol. 1992 Jun;142(1):103-13
1586951
Cell. 1994 Aug 26;78(4):535-8
8069904
J Comp Neurol. 1978 May 1;179(1):223-44
8980725
Cancer Immunol Immunother. 2003 Jan;52(1):1-9
12536234
Proc Natl Acad Sci U S A. 1986 Aug;83(16):6007-11
3090548
Nature. 1984 Jul 19-25;310(5974):246-9
6462208
Cancer Res. 2005 Dec 1;65(23):11146-55
16322265
Int Immunol. 2003 Mar;15(3):331-9
12618477
Mod Pathol. 1995 Apr;8(3):333-8
7617661
J Biol Chem. 2004 Dec 17;279(51):53062-70
15471856
Trends Immunol. 2007 Mar;28(3):115-23
17261379
Curr Biol. 2003 Mar 4;13(5):394-400
12620187
J Comp Neurol. 1970 Aug;139(4):473-500
4195699
Cell. 2003 Mar 7;112(5):607-18
12628182
Proc Natl Acad Sci U S A. 1984 Oct;81(20):6476-80
6436814